Nurix Therapeutics Share Price (NASDAQ: NRIX)

$9.34

▲

-0.07

(-0.74%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Nurix Therapeutics Stock chart to analyse performance

Nurix Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$9.30
Today's High:$9.51
$9.34
0.43%
Downside
Day's Volatility :2.21%
Upside
1.79%
52 Weeks Low:$8.18
52 Weeks High:$29.56
$9.34
12.42%
Downside
52 Weeks Volatility :72.33%
Upside
68.4%

Nurix Therapeutics Stock Returns

Period	Nurix Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-23.11%	3.6%	0.0%
6 Months	-34.21%	-7.7%	0.0%
1 Year	-62.45%	-12.6%	0.0%
3 Years	-43.04%	9.5%	-4.7%

Nurix Therapeutics Inc Key Stats

Check Nurix Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$9.41
Open	$9.45
Today's High	$9.51
Today's Low	$9.3
Market Capitalization	$730.1M
Today's Volume	$1.8M
52 Week High	$29.56
52 Week Low	$8.18
Revenue TTM	$88.4M
EBITDA	$-222.2M
Earnings Per Share (EPS)	$-2.6
Profit Margin	-234.57%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-50.67%

Stock Returns calculator for Nurix Therapeutics Stock including INR - Dollar returns

The Nurix Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Nurix Therapeutics investment value today

Current value as on today

₹42,348

Returns

₹57,652

(-57.65%)

Returns from Nurix Therapeutics Stock

₹62,937 (-62.94%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Nurix Therapeutics Stock

-94%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Nurix Therapeutics Stock from India on INDmoney has decreased by -94% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Nurix Therapeutics Inc

Name
Holdings %
Name
Holdings %
FMR Inc
13.52%
BlackRock Inc
10.45%
Deep Track Capital, LP
7.93%
Vanguard Group Inc
5.84%
COMMODORE CAPITAL LP
5.17%
Baker Bros Advisors LP
5.08%

Analyst Recommendation on Nurix Therapeutics Stock

Rating

Trend

Buy

88%Buy

11%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Nurix Therapeutics(by analysts ranked 0 to 5 stars)

Nurix Therapeutics Share Price Target

What analysts predicted

Upside of 219.41%

Target:

$29.83

Current:

$9.34

Nurix Therapeutics share price target is $29.83, a slight Upside of 219.41% compared to current price of $9.34 as per analysts' prediction.

Nurix Therapeutics Stock Insights

Price Movement
In the last 7 days, NRIX stock has moved down by -7.9%
Increasing Revenue
Revenue is up for the last 5 quarters, 12.09M → 44.05M (in $), with an average increase of 23.8% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -58.54M → -43.46M (in $), with an average increase of 16.8% per quarter
NRIX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 132.9%
NRIX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 152.0%
Price to Sales
ForNRIX every $1 of sales, investors are willing to pay $8.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Nurix Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$31.1M	↓ 16.91%
Net Income	$-21.7M	↑ 130.15%
Net Profit Margin	-69.74%	↓ 44.56%

	FY20	Y/Y Change
Revenue	$17.8M	↓ 42.73%
Net Income	$-43.2M	↑ 99.28%
Net Profit Margin	-242.66%	↓ 172.92%

	FY21	Y/Y Change
Revenue	$29.8M	↑ 66.95%
Net Income	$-117.2M	↑ 171.02%
Net Profit Margin	-393.93%	↓ 151.27%

	FY22	Y/Y Change
Revenue	$38.6M	↑ 29.84%
Net Income	$-166.0M	↑ 41.68%
Net Profit Margin	-429.87%	↓ 35.94%

	FY23	Y/Y Change
Revenue	$77.0M	↑ 99.31%
Net Income	$-143.9M	↓ 13.31%
Net Profit Margin	-186.98%	↑ 242.89%

	FY24	Y/Y Change
Revenue	$54.5M	↓ 29.15%
Net Income	$-193.6M	↑ 34.47%
Net Profit Margin	-354.85%	↓ 167.87%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$16.6M	↑ 9.41%
Net Income	$-41.5M	↓ 1.04%
Net Profit Margin	-250.33%	↑ 26.44%

	Q2 FY24	Q/Q Change
Revenue	$12.1M	↓ 27.09%
Net Income	$-44.5M	↑ 7.29%
Net Profit Margin	-368.39%	↓ 118.06%

	Q3 FY24	Q/Q Change
Revenue	$12.6M	↑ 4.1%
Net Income	$-49.0M	↑ 9.9%
Net Profit Margin	-388.91%	↓ 20.52%

	Q4 FY24	Q/Q Change
Revenue	$13.3M	↑ 5.53%
Net Income	$-58.5M	↑ 19.6%
Net Profit Margin	-440.75%	↓ 51.84%

	Q1 FY25	Q/Q Change
Revenue	$18.5M	↑ 38.91%
Net Income	$-56.4M	↓ 3.75%
Net Profit Margin	-305.38%	↑ 135.37%

	Q2 FY25	Q/Q Change
Revenue	$44.1M	↑ 138.75%
Net Income	$-43.5M	↓ 22.87%
Net Profit Margin	-98.66%	↑ 206.72%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-13.9M	↑ 353.83%

	FY20	Y/Y Change
Profit	$17.8M	↓ 228.11%

	FY21	Y/Y Change
Profit	$29.8M	↑ 66.95%

	FY22	Y/Y Change
Profit	$38.6M	↑ 29.84%

	FY23	Y/Y Change
Profit	$63.3M	↑ 63.96%

	FY24	Y/Y Change
Profit	$38.1M	↓ 39.81%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$12.7M	↑ 11.36%

	Q2 FY24	Q/Q Change
Profit	$8.0M	↓ 36.99%

	Q3 FY24	Q/Q Change
Profit	$4.1M	↓ 48.27%

	Q4 FY24	Q/Q Change
Profit	$13.3M	↑ 220.95%

	Q1 FY25	Q/Q Change
Profit	$18.5M	↑ 38.91%

	Q2 FY25	Q/Q Change
Profit	$44.1M	↑ 138.75%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$601.0K	↓ 101.9%
Investing Cash Flow	$8.5M	↓ 78.75%
Financing Cash Flow	$126.0K	↓ 76.18%

	FY20	Y/Y Change
Operating Cash Flow	$-80.0K	↓ 113.31%
Investing Cash Flow	$-254.4M	↓ 3093.69%
Financing Cash Flow	$339.0M	↑ 268966.67%

	FY21	Y/Y Change
Operating Cash Flow	$-84.4M	↑ 105356.25%
Investing Cash Flow	$-108.3M	↓ 57.45%
Financing Cash Flow	$153.9M	↓ 54.61%

	FY22	Y/Y Change
Operating Cash Flow	$-159.8M	↑ 89.42%
Investing Cash Flow	$27.2M	↓ 125.12%
Financing Cash Flow	$117.2M	↓ 23.84%

	FY23	Y/Y Change
Operating Cash Flow	$-81.4M	↓ 49.09%
Investing Cash Flow	$68.3M	↑ 151.13%
Financing Cash Flow	$3.2M	↓ 97.25%

	FY24	Y/Y Change
Operating Cash Flow	$-172.6M	↑ 112.11%
Investing Cash Flow	$-257.7M	↓ 477.32%
Financing Cash Flow	$485.7M	↑ 14996.89%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-42.0M	↓ 292.89%
Investing Cash Flow	$35.5M	↓ 347.08%
Financing Cash Flow	$1.6M	↑ 23100.0%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-39.7M	↓ 5.35%
Investing Cash Flow	$-131.1M	↓ 469.08%
Financing Cash Flow	$237.8M	↑ 14539.9%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-42.2M	↑ 6.23%
Investing Cash Flow	$-21.3M	↓ 83.72%
Financing Cash Flow	$45.8M	↓ 80.75%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-48.8M	↑ 15.59%
Investing Cash Flow	$-140.8M	↑ 559.9%
Financing Cash Flow	$200.5M	↑ 338.11%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-61.1M	↑ 25.3%
Investing Cash Flow	$25.5M	↓ 118.13%
Financing Cash Flow	$1.5M	↓ 99.27%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-63.2M	↑ 3.4%
Investing Cash Flow	$71.5M	↑ 180.03%
Financing Cash Flow	$6.0K	↓ 99.59%

Nurix Therapeutics Technicals Summary

Sell

Neutral

Buy

Nurix Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Nurix Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Nurix Therapeutics Inc	-15.44%	-34.21%	-62.45%	-43.04%	-65.77%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Nurix Therapeutics Inc	NA	NA	NA	-2.96	-0.51	-0.26	NA	5.86
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Nurix Therapeutics Inc	Buy	$730.1M	-65.77%	NA	-234.57%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Nurix Therapeutics Inc

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Organization	Nurix Therapeutics
Employees	286
CEO	Dr. Arthur T. Sands M.D., Ph.D.
Industry	Health Technology

Key Management of Nurix Therapeutics Inc

Name	Title
Dr. Arthur T. Sands M.D., Ph.D.	CEO, President & Director
Mr. Johannes Van Houte	Chief Financial Officer
Dr. Gwenn M. Hansen Ph.D.	Chief Scientific Officer
Dr. Christine Ring J.D., Ph.D.	Chief Legal Officer, Secretary & Chief Compliance Officer
Dr. John Kuriyan Ph.D.	Founder & Member of Scientific Advisory Board
Dr. Arthur Weiss M.D., Ph.D.	Founder & Member of Scientific Advisory Board
Rita Kwong	Senior Accounting Manager
Dr. Pasit Phiasivongsa Ph.D.	Chief Technical Officer
Dr. Jason Kantor Ph.D.	Chief Business Officer
Mr. Christopher B. Phelps Ph.D.	Senior VP & Head of Early Drug Discovery

Important FAQs about investing in NRIX Stock from India :

What is Nurix Therapeutics share price today?

Nurix Therapeutics share price today is $9.34 as on August 30, 2025 at 1:29 am IST at the close of the market. Nurix Therapeutics share today touched a day high of $9.51 and a low of $9.30.

What is the 52 week high and 52 week low for Nurix Therapeutics share?

Nurix Therapeutics share touched a 52 week high of $29.56 and a 52 week low of $8.18. Nurix Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $9.34, lower by 68.4% versus the 52 week high.

How to invest in Nurix Therapeutics Stock (NRIX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Nurix Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Nurix Therapeutics Shares that will get you 0.1606 shares as per Nurix Therapeutics share price of $9.34 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Nurix Therapeutics Stock (NRIX) from India?

Indian investors can start investing in Nurix Therapeutics (NRIX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Nurix Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Nurix Therapeutics share’s latest price of $9.34 as on August 30, 2025 at 1:29 am IST, you will get 1.0707 shares of Nurix Therapeutics. Learn more about fractional shares .

What are the returns that Nurix Therapeutics has given to Indian investors in the last 5 years?

Nurix Therapeutics stock has given -65.77% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?